These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 14734884

  • 1. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 2. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
    Kullberg-Lindh C, Saalman R, Olausson M, Herlenius G, Lindh M.
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
    [Abstract] [Full Text] [Related]

  • 5. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Kamei H, Ito Y, Kawada J, Ogiso S, Onishi Y, Komagome M, Kurata N, Ogura Y.
    Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384
    [Abstract] [Full Text] [Related]

  • 6. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
    Soriano-López DP, Alcántar-Fierros JM, Hernández-Plata JA, González-Jorge AL, Velázquez-Ramos S, Flores-Hernández MA, Fuentes V, Castañeda P, Nieto J, Sánchez JL, López B, Valencia-Mayoral P, Varela-Fascinetto G.
    Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
    [Abstract] [Full Text] [Related]

  • 7. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 8. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 27; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 9. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 27; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 10. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
    Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA.
    Am J Transplant; 2005 Sep 27; 5(9):2222-8. PubMed ID: 16095501
    [Abstract] [Full Text] [Related]

  • 11. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 27; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 12. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Jun 27; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 13. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM.
    Transplantation; 2002 May 27; 73(10):1603-10. PubMed ID: 12042647
    [Abstract] [Full Text] [Related]

  • 14. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS, Ho MC, Hu RH, Wu JF, Chen HL, Ni YH, Hsu HY, Jeng YM, Chang MH.
    J Formos Med Assoc; 2019 Sep 27; 118(9):1362-1368. PubMed ID: 30612881
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun 27; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

  • 16. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
    Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ.
    Transplantation; 2002 Aug 15; 74(3):367-72. PubMed ID: 12177616
    [Abstract] [Full Text] [Related]

  • 17. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 18. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.
    Am J Transplant; 2014 Apr 27; 14(4):857-66. PubMed ID: 24666832
    [Abstract] [Full Text] [Related]

  • 19. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug 27; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 20. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation.
    Gridelli B, Spada M, Riva S, Colledan M, Segalin A, Lucianetti A, Sonzogni A, Furione M, Baldanti F, Torre G.
    Transpl Int; 2000 Aug 27; 13 Suppl 1():S399-401. PubMed ID: 11112041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.